

Doncaster & Bassetlaw Medicines Formulary

Section 4.4: CNS Stimulants and Drugs Used for ADHD (attention-deficit hyperactivity disorder)

Approved by Drug and Therapeutics Committee: December 2018
Review Date: December 2021

Prescribing Guidance:

Items for Restricted Prescribing:

- Atomoxetine 10mg, 18mg, 25mg, 40mg and 60mg Capsules
- Dexamfetamine Sulphate 5mg Tablets
- Methylphenidate 5mg and 10mg Tablets
- Methylphenidate (Concerta XL) 18mg, 27mg, 36mg and 54mg Modified Release Tablets
- Methylphenidate (Equasym XL, Medikinet XL) 10mg, 20mg, 30mg and 40mg Modified Release Tablets
- Lisdexamphetamine 30mg, 50mg and 70mg Capsules
- Guanfesin 1mg, 2mg, 3mg and 4mg Modified Release Tablets

A [NICE technology appraisal](#) is available on their website regarding the use of medication for ADHD (attention deficit hyperactivity disorder) in children and adolescents.

See also [RDASH formulary guidance](#) for ADHD

There is a local [shared care guideline](#) for the prescribing of ADHD treatments.

KEY: [UL] Unlicensed Preparation; **Drug** – first line choice; **Drug** – hospital only; **Drug** – Amber (TLS), **Drug** – Red (TLS), see <http://medicinesmanagement.doncasterpct.nhs.uk/>
Prescribing outside this formulary should only take place via a New Product Request